Fourth-generation fluoroquinolones in tuberculosis.
Rieder
Hans L
HL
International Union Against Tuberculosis and Lung Disease, 3038 Kirchlindach, Switzerland. TBRieder@tbrieder.org
D000890:Anti-Infective Agents / Q000627:therapeutic use*; D001372:Aza Compounds / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D055808:Drug Discovery; D004359:Drug Therapy, Combination; D024841:Fluoroquinolones; D006801:Humans; D000077266:Moxifloxacin; D011804:Quinolines / Q000627:therapeutic use*; D013183:Sputum / Q000382:microbiology; D013997:Time Factors; D016896:Treatment Outcome; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy* / Q000382:microbiology; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy* / Q000382:microbiology
D000890:Anti-Infective Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D000077266:Moxifloxacin